Rodriguez J M, Khan A A
Al-Hada Armed Forces Hospital, Al-Taif, Saudi Arabia.
Clin Oncol (R Coll Radiol). 1995;7(2):113-6. doi: 10.1016/s0936-6555(05)80813-1.
The clinical outcome of 23 patients with high grade diffuse large cell immunoblastic lymphoma (Working Formulation, category H) treated by an intensive shortened schedule regimen of chemotherapy is described. Alternating cycles of cyclophosphamide, doxorubicin, vincristine, bleomycin and prednisolone, and ifosfamide, etoposide and methotrexate were given over an 18-week (range 16.0-20.8) period. External beam radiotherapy was administered as consolidation therapy to sites of original bulky disease in 17 patients. Treatment was well tolerated, though there were two toxic deaths. A 90% response rate was obtained. Sixteen of 18 patients followed for a minimum of 36 months are alive and in complete remission, representing a disease free survival of 69.5%; two further patients are alive following autologous bone marrow transplant. The 3-year disease free survival was 73% (+/- 9%) and the overall 3-year survival 78% (+/- 9%).
本文描述了采用强化短程化疗方案治疗的23例高级别弥漫性大细胞免疫母细胞性淋巴瘤（工作分类，H类）患者的临床结果。在18周（范围16.0 - 20.8周）的时间内，交替给予环磷酰胺、阿霉素、长春新碱、博来霉素和泼尼松龙，以及异环磷酰胺、依托泊苷和甲氨蝶呤的周期。17例患者接受了体外照射放疗，作为对原有大块病灶部位的巩固治疗。尽管有两例因毒性死亡，但治疗耐受性良好。获得了90%的缓解率。18例至少随访36个月的患者中有16例存活且完全缓解，无病生存率为69.5%；另外两名患者在自体骨髓移植后存活。3年无病生存率为73%（±9%），总体3年生存率为78%（±9%）。
